The second reported trial, LEADER, with modified human GLP-1 receptor agonist liraglutide, demonstrated a reduction in three-point MACE by 13%, driven mainly by a lower rate of death from cardiovascular disease in 9340 patients with T2DM and high cardiovascular risk [35]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.